

Kenneth Aldape

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/57280/publications.pdf>

Version: 2024-02-01

107
papers

17,613
citations

81900

39
h-index

51608

86
g-index

112
all docs

112
docs citations

112
times ranked

20402
citing authors

#	ARTICLE	IF	CITATIONS
1	The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2013, 155, 462-477.	28.9	3,979
2	Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. <i>Cancer Cell</i> , 2010, 17, 510-522.	16.8	2,078
3	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
4	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. <i>Cancer Cell</i> , 2012, 22, 425-437.	16.8	1,551
5	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015, 27, 728-743.	16.8	933
6	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
7	cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". <i>Acta Neuropathologica</i> , 2018, 136, 805-810.	7.7	599
8	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 509-520.	27.6	540
9	Glioblastoma: pathology, molecular mechanisms and markers. <i>Acta Neuropathologica</i> , 2015, 129, 829-848.	7.7	503
10	Paediatric and adult glioblastoma: multifactorial (epi)genomic culprits emerge. <i>Nature Reviews Cancer</i> , 2014, 14, 92-107.	28.4	469
11	cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-NOW meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020, 30, 844-856.	4.1	363
12	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. <i>Acta Neuropathologica</i> , 2020, 139, 603-608.	7.7	344
13	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120.	27.8	320
14	Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas. <i>Cancer Immunology Research</i> , 2013, 1, 112-122.	3.4	192
15	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019, 21, 901-910.	1.2	184
16	A clinically applicable integrative molecular classification of meningiomas. <i>Nature</i> , 2021, 597, 119-125.	27.8	180
17	Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. <i>Nature Medicine</i> , 2020, 26, 1044-1047.	30.7	170
18	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC Tj ETQq0 0 0 rgBT /Overlock 10 <i>Oncology, The</i> , 2021, 22, 813-823.	10.7	132

#	ARTICLE	IF	CITATIONS
19	MGMT Status as a Clinical Biomarker in Glioblastoma. Trends in Cancer, 2020, 6, 380-391.	7.4	131
20	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. Journal of Clinical Investigation, 2018, 129, 223-229.	8.2	130
21	Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care. Npj Precision Oncology, 2017, 1, 22.	5.4	127
22	A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma. Journal of Neuropathology and Experimental Neurology, 2018, 77, 1039-1054.	1.7	105
23	Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-Oncology, 2015, 17, 440-447.	1.2	102
24	Advances in multidisciplinary therapy for meningiomas. Neuro-Oncology, 2019, 21, i18-i31.	1.2	102
25	Imaging and diagnostic advances for intracranial meningiomas. Neuro-Oncology, 2019, 21, i44-i61.	1.2	100
26	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology, 2021, 39, 3839-3852.	1.6	93
27	Molecular and translational advances in meningiomas. Neuro-Oncology, 2019, 21, i4-i17.	1.2	92
28	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
29	A molecularly integrated grade for meningioma. Neuro-Oncology, 2022, 24, 796-808.	1.2	83
30	DNA Methylation Profiling: An Emerging Paradigm for Cancer Diagnosis. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 295-321.	22.4	83
31	Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients. Neuro-Oncology, 2016, 18, 1209-1218.	1.2	75
32	World Health Organization 2016 Classification of Central Nervous System Tumors. Neurologic Clinics, 2018, 36, 439-447.	1.8	64
33	CIC protein instability contributes to tumorigenesis in glioblastoma. Nature Communications, 2019, 10, 661.	12.8	63
34	A change at the helm of Neuro-Oncology. Neuro-Oncology, 2018, 20, 1-1.	1.2	62
35	Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell, 2021, 184, 2487-2502.e13.	28.9	60
36	Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. Brain Pathology, 2017, 27, 411-418.	4.1	58

#	ARTICLE	IF	CITATIONS
37	Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas. <i>Journal of Neurosurgery</i> , 2016, 125, 431-440.	1.6	49
38	<i>In vitro</i> and <i>in vivo</i> identification of clinically approved drugs that modify ACE2 expression. <i>Molecular Systems Biology</i> , 2020, 16, e9628.	7.2	47
39	High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 101.	5.2	45
40	Proteomic analysis of meningiomas reveals clinically distinct molecular patterns. <i>Neuro-Oncology</i> , 2019, 21, 1028-1038.	1.2	42
41	Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. <i>Neuro-Oncology</i> , 2022, 24, 571-581.	1.2	39
42	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	1.2	39
43	Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. <i>Neuro-Oncology</i> , 2023, 25, 339-350.	1.2	35
44	DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology. <i>Neuro-Oncology</i> , 2021, 23, S16-S29.	1.2	34
45	Recurrent fusions in <i>PLAGL1</i> define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2021, 142, 827-839.	7.7	33
46	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in <i>SMARCE1</i> . <i>Acta Neuropathologica</i> , 2021, 141, 281-290.	7.7	31
47	TNF \pm secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy. <i>Acta Neuropathologica Communications</i> , 2021, 9, 67.	5.2	28
48	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial</i> . <i>Clinical Cancer Research</i> , 2022, 28, 2527-2535.	7.0	27
49	Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 547-574.	2.5	25
50	Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. <i>Acta Neuropathologica</i> , 2021, 142, 179-189.	7.7	24
51	A T cell resilience model associated with response to immunotherapy in multiple tumor types. <i>Nature Medicine</i> , 2022, 28, 1421-1431.	30.7	23
52	Molecular Signatures for Tumor Classification. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 881-891.	2.8	22
53	Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 37.	5.2	20
54	Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma. <i>Neuro-Oncology</i> , 2017, 19, 1503-1510.	1.2	18

#	ARTICLE	IF	CITATIONS
55	Minimalist approaches to cancer tissue-of-origin classification by DNA methylation. <i>Modern Pathology</i> , 2020, 33, 1874-1888.	5.5	18
56	Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types. <i>Cancer Research</i> , 2022, 82, 2076-2083.	0.9	18
57	A novel ATXN1-DUX4 fusion expands the spectrum of "CIC-rearranged sarcoma"™ of the CNS to include non-CIC alterations. <i>Acta Neuropathologica</i> , 2021, 141, 619-622.	7.7	16
58	5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma. <i>Acta Neuropathologica</i> , 2018, 135, 617-634.	7.7	15
59	Norrin mediates tumor-promoting and -suppressive effects in glioblastoma via Notch and Wnt. <i>Journal of Clinical Investigation</i> , 2020, 130, 3069-3086.	8.2	15
60	Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. <i>Cancers</i> , 2021, 13, 6092.	3.7	14
61	High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. <i>Acta Neuropathologica</i> , 2022, 143, 403-414.	7.7	13
62	Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study. <i>Neuro-Oncology Practice</i> , 2021, 8, 460-474.	1.6	12
63	Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology. <i>Acta Neuropathologica Communications</i> , 2022, 10, 19.	5.2	11
64	c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein. <i>Molecular Cancer Research</i> , 2020, 18, 774-786.	3.4	10
65	DNA methylation analysis of glioblastomas harboring FGFR3-TACC3 fusions identifies a methylation subclass with better patient survival. <i>Acta Neuropathologica</i> , 2022, 144, 155-157.	7.7	10
66	Immune cell deconvolution of bulk DNA methylation data reveals an association with methylation class, key somatic alterations, and cell state in glial/glioneuronal tumors. <i>Acta Neuropathologica Communications</i> , 2021, 9, 148.	5.2	9
67	BRAF V600E mutant oligodendroglioma-like tumors with chromosomal instability in adolescents and young adults. <i>Brain Pathology</i> , 2020, 30, 515-523.	4.1	8
68	MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. <i>Cell Reports Methods</i> , 2022, 2, 100136.	2.9	8
69	Recurrent ACVR1 mutations in posterior fossa ependymoma. <i>Acta Neuropathologica</i> , 2022, 144, 373-376.	7.7	7
70	A simple, high-throughput method of protein and label removal from extracellular vesicle samples. <i>Nanoscale</i> , 2021, 13, 3737-3745.	5.6	6
71	Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa124.	0.7	5
72	The Alliance AMBUSH Trial: Rationale and Design. <i>Cancers</i> , 2022, 14, 414.	3.7	5

#	ARTICLE	IF	CITATIONS
73	NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumorsâ€™ Histone Mutated Midline Glioma Workshop Proceedings. Neuro-Oncology Advances, 2020, 2, vdaa007.	0.7	4
74	Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias. JCO Precision Oncology, 2021, 5, 1147-1150.	3.0	4
75	The multiforme of glioblastoma. Neuro-Oncology, 2018, 20, 437-438.	1.2	3
76	Morphologic and Molecular Aspects of Glioblastomas. Neurosurgery Clinics of North America, 2021, 32, 149-158.	1.7	3
77	Report of Canonical <i>BCR</i> - <i>ABL1</i> Fusion in Glioblastoma. JCO Precision Oncology, 2021, 5, 1348-1353.	3.0	3
78	Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis. Neuro-Oncology, 2021, 23, 795-802.	1.2	3
79	Astroblastomas exhibit radial glia stem cell lineages and differential expression of imprinted and X-inactivation escape genes. Nature Communications, 2022, 13, 2083.	12.8	3
80	Bringing IDH into the Fold. Cancer Cell, 2016, 29, 139-140.	16.8	2
81	IDH mutation testing in gliomasâ€™ where do we draw the line?. Neuro-Oncology, 2017, 19, 1568-1569.	1.2	2
82	CTIM-32. IMMUNE CHECKPOINT INHIBITOR NIVOLUMAB IN PEOPLE WITH RECURRENT SELECT RARE CNS CANCERS: RESULTS OF INTERIM ANALYSIS IN A HEAVILY PRETREATED COHORT. Neuro-Oncology, 2021, 23, vi57-vi58.	1.2	2
83	ETMR-06. Molecular and clinical characteristics of CNS tumors with <i>BCOR</i> (L1) fusion/internal tandem duplication. Neuro-Oncology, 2022, 24, i50-i50.	1.2	2
84	71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES. Neuro-Oncology Advances, 2020, 2, ii15-ii15.	0.7	1
85	Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. Frontiers in Oncology, 2020, 10, 601452.	2.8	1
86	Diagnostic and Prognostic Implications of GNAS Inactivation in Sonic Hedgehogâ€™ Activated Medulloblastoma: Case Report with Comprehensive Molecular Profiling and Review of Literature. JCO Precision Oncology, 2022, 6, e2100403.	3.0	1
87	RARE-15. Astroblastoma, <i>MN1</i> altered comprises two molecularly and clinically distinct subgroups defined by the fusion partners <i>BEND2</i> and <i>CXXC5</i> . Neuro-Oncology, 2022, 24, i12-i13.	1.2	1
88	RESICstance Is Futileâ€™ But Not in Glioblastoma. Cancer Cell, 2014, 26, 156-157.	16.8	0
89	CADD-49. IDENTIFICATION AND VALIDATION OF AZOLES AS HK2 INHIBITORS IN GLIOBLASTOMA <i>IN VITRO</i> AND <i>IN VIVO</i> . Neuro-Oncology, 2018, 20, vi282-vi282.	1.2	0
90	BSCI-26. COMPARATIVE METHYLATION PROFILING OF EGFR MUTANT LUNG ADENOCARCINOMA AND PAIRED BRAIN METASTASIS. Neuro-Oncology Advances, 2019, 1, i5-i6.	0.7	0

#	ARTICLE	IF	CITATIONS
91	Highlights of the inaugural ten “ the launch of Neuro-Oncology Advances. Neuro-Oncology Advances, 2019, 1, vdz016.	0.7	0
92	Reply to “Assembling the brain trust: the multidisciplinary imperative in neuro-oncology”™. Nature Reviews Clinical Oncology, 2019, 16, 522-523.	27.6	0
93	Needle in a haystack: identifying drivers of malignant transformation in neurofibromas. Neuro-Oncology, 2019, 21, 961-962.	1.2	0
94	CMET-30. COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS. Neuro-Oncology, 2019, 21, vi58-vi58.	1.2	0
95	CMET-32. DNA METHYLATION ALTERATIONS IN LUNG ADENOCARCINOMAS THAT DEVELOP BRAIN METASTASES. Neuro-Oncology, 2019, 21, vi58-vi58.	1.2	0
96	PATH-21. CLINICAL UTILITY OF DNA METHYLATION PROFILING FOR DIAGNOSIS OF CHALLENGING CENTRAL NERVOUS SYSTEM TUMORS: THE TORONTO EXPERIENCE. Neuro-Oncology, 2019, 21, vi147-vi147.	1.2	0
97	Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. Neuro-Oncology, 2021, 23, 506-507.	1.2	0
98	MOMC-3. Hypermethylation and overexpression of HOX genes are poor prognosticators in Lower-Grade Glioma. Neuro-Oncology Advances, 2021, 3, ii4-ii4.	0.7	0
99	Pediatric Gliomas Presenting with Gliomatosis-Like Spread, Lack of Contrast Enhancement, EGFR Mutation, and TERT Promoter Variants. Journal of Neuropathology and Experimental Neurology, 2021, 80, 1134-1136.	1.7	0
100	Brief Report: Meningiomas in Patients with Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations. Journal of Thoracic Oncology, 2021, , .	1.1	0
101	INN-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC. Neuro-Oncology, 2021, 23, vi111-vi111.	1.2	0
102	PATH-18. INTEGRATING TUMOR MICROENVIRONMENT WITH GENOMIC ABERRATIONS AND TUMOR CLASS IN ADULT GLIAL/GLIONEURONAL TUMORS BY DECONVOLUTION OF BULK METHYLATION DATA. Neuro-Oncology, 2021, 23, vi118-vi118.	1.2	0
103	DDRE-39. REPURPOSING CHEMOTHERAPIES AGAINST HIGH-RISK MENINGIOMAS WITH GUIDANCE BY METHYLATION PROFILES. Neuro-Oncology, 2021, 23, vi82-vi83.	1.2	0
104	EPCO-32. IDENTIFICATION OF PROGNOSTIC CHORDOMA SUBGROUPS USING DNA METHYLATION SIGNATURES IN TISSUE AND PLASMA. Neuro-Oncology, 2021, 23, vi9-vi9.	1.2	0
105	PATH-08. PROGNOSTIC IMPLICATIONS FROM LONG-TERM SURVIVORS (LTS) OF GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi116-vi116.	1.2	0
106	NCOG-34. A DESCRIPTIVE ANALYSIS OF GLIOMATOSIS CEREBRI CASES, COMPARED ACCORDING TO IDH STATUS. Neuro-Oncology, 2021, 23, vi159-vi159.	1.2	0
107	PATH-46. DIAGNOSTIC IMPACT OF THE CNS TUMOR METHYLATION PROFILING IN A NEUROPATHOLOGY CONSULT PRACTICE. Neuro-Oncology, 2021, 23, vi125-vi126.	1.2	0